SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (3004)5/26/1999 1:46:00 AM
From: Art Vandelay AIA  Read Replies (3) of 10280
 
This is not the first time that the IGE issue has surfaced. I need to be brief because my wife is waiting for me, but I believe that the drug if successful will only address a small market. Basically, the most severe cases of allergy. Even though Claritin is arguably the most effect (could substitute Zyrtec or Allegra) for this point. People still use OTC products that are less effective and mostly drowsy, but still garner over 30% of the market. The factors are cost, convenience, and severity of allergy. IGE won't compete well buy these standards IMO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News